Mitogen-activated protein kinase kinase 2 (MEK2) (MEK2)

Mitogen-activated protein kinase kinase 2 (MEK2), also known as MAP2K2, is a dual-specificity protein kinase that serves as a critical node in the highly conserved MAPK/ERK signaling pathway [1, 3]. It is activated by RAF kinases through phosphorylation on specific serine residues and, in turn, phosphorylates and activates the downstream effectors ERK1 and ERK2 [3, 9]. This signaling cascade is essential for regulating fundamental cellular processes, including growth, proliferation, differentiation, and survival in response to extracellular stimuli like growth factors and cytokines [3, 10]. Dysregulation of this pathway, often through activating mutations in upstream components like BRAF or NRAS, leads to the constitutive activation of MEK2, which is a hallmark of various malignancies such as melanoma and non-small cell lung cancer [1, 4, 12]. Binimetinib is a potent, selective, and orally available allosteric inhibitor that targets both MEK1 and MEK2 [2, 8]. By binding to a site adjacent to the ATP-binding pocket, it prevents the conformational changes necessary for kinase activity, thereby blocking the activation of ERK and inhibiting the growth of tumor cells that depend on aberrant MAPK signaling [2, 4]. In clinical practice, binimetinib is frequently used in combination with BRAF inhibitors like encorafenib to achieve more comprehensive pathway blockade and delay the emergence of resistance [1, 5]. Beyond its role in oncology, germline mutations in the MAP2K2 gene are associated with cardiofaciocutaneous syndrome, highlighting its importance in normal development [9, 11]. Therapeutic targeting of MEK2 requires careful monitoring for specific toxicities, including ocular and cardiac adverse events, which are characteristic of this drug class [8, 13].

Other names

MAP2K2MKK2PRKMK2MAP kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 2ERK activator kinase 2

Allosteric inhibition of MEK1 and MEK2 kinase activity, preventing the phosphorylation and activation of downstream ERK1/2.